###begin article-title 0
Genes influencing coagulation and the risk of aneurysmal subarachnoid hemorrhage, and subsequent complications of secondary cerebral ischemia and rebleeding
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 188 196 <span type="species:ncbi:9606">patients</span>
We investigated whether genes influencing coagulation are associated with the occurrence of aneurysmal subarachnoid hemorrhage (SAH) and with secondary cerebral ischemia and rebleeding in patients with aneurysmal SAH.
###end p 2
###begin title 3
Method
###end title 3
###begin p 4
###xml 228 236 <span type="species:ncbi:9606">patients</span>
###xml 327 335 <span type="species:ncbi:9606">patients</span>
Genotyping for factor V Leiden (G1691A), prothrombin G20210A, methylenetetetrahydrofolate reductase (MTHFR) C677T, factor XIII subunit A Val34Leu, Tyr204Phe and Pro564Leu, and factor XIII subunit B His95Arg was performed in 208 patients with aneurysmal SAH and in 925 controls. Secondary cerebral ischemia occurred in 49 (24%) patients and rebleeding in 28 (14%) during their clinical course of 3 months after the aneurysmal SAH. The risk of aneurysmal SAH was assessed as odds ratio (OR) with 95% confidence interval (95% CI). The risk of secondary cerebral ischemia and rebleeding was assessed as hazard ratio (HR) with 95% CI using Cox regression.
###end p 4
###begin title 5
Findings
###end title 5
###begin p 6
###xml 116 124 <span type="species:ncbi:9606">patients</span>
Carriers of the subunit B His95Arg factor XIII polymorphism had an increased risk of aneurysmal SAH with 23% of the patients homozygous or heterozygous for the variant allele compared to 17% of control subjects (OR 1.5, 95% CI 1.0-2.2). For the remaining genetic variants no effect on the risk of aneurysmal SAH could be demonstrated. A clear relation with the risk of secondary cerebral ischemia and of rebleeding could not be established for any of the genetic variants.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 29 37 <span type="species:ncbi:9606">patients</span>
###xml 317 325 <span type="species:ncbi:9606">patients</span>
###xml 442 450 <span type="species:ncbi:9606">patients</span>
We found that aneurysmal SAH patients are more often carriers of the subunit B His95Arg factor XIII polymorphism compared to controls. This suggests that carriers of the subunit B His95Arg factor XIII polymorphism have an increased risk of aneurysmal SAH. Larger studies should confirm our results. As aneurysmal SAH patients who died soon after admission could not be included in the present study, our results only apply to a population of patients who survived the initial hours after the hemorrhage. For the other studied genetic factors involved in coagulation, no association with the occurrence of aneurysmal SAH or with the occurrence of secondary cerebral ischemia or rebleeding after aneurysmal SAH could be demonstrated.
###end p 8
###begin title 9
Keywords
###end title 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 141 143 141 143 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 229 231 229 231 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 383 384 383 384 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 386 387 386 387 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 389 391 389 391 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 470 471 470 471 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 473 474 473 474 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 476 478 476 478 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 590 591 590 591 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 703 705 703 705 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 237 245 <span type="species:ncbi:9606">patients</span>
###xml 460 468 <span type="species:ncbi:9606">patients</span>
Spontaneous subarachnoid hemorrhage (SAH) from rupture of an intracranial saccular aneurysm has an incidence of approximately 8 per 100,000 [20]. The prognosis after aneurysmal SAH is poor with a case fatality rate of 32 to 67% [15]. In patients who survive the initial hours after aneurysmal SAH, secondary cerebral ischemia and rebleeding are major causes of death and disability [4, 6, 25]. Secondary cerebral ischemia occurs in approximately 25% to 35% of patients [4, 6, 25] during the clinical course. Rebleeding within the first 4 weeks occurs in 40% if the aneurysm is not treated [6] and remains an important cause of death, even if the aim is to occlude the aneurysm early after the bleeding [27].
###end p 11
###begin p 12
###xml 256 258 256 258 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 385 387 385 387 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 565 567 565 567 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 569 571 569 571 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 429 437 <span type="species:ncbi:9606">patients</span>
Coagulation factors may be involved in aneurysmal SAH and its subsequent complications. The causes of SAH without a detectable aneurysm include bleeding disorders, but the role of coagulation disorders in the occurrence of aneurysmal SAH is not yet known [26]. A possible higher risk of aneurysmal SAH has been suggested for a coagulation factor XIII subunit A Tyr204Phe polymorphism [24]. Studies with antifibrinolytic drugs in patients with SAH found that this treatment reduces the occurrence of rebleeding but increases the risk of secondary cerebral ischemia [14, 28]. Thus, antifibrinolytic drugs have an opposite effect on the risks of rebleeding and secondary cerebral ischemia.
###end p 12
###begin p 13
###xml 158 160 158 160 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 517 519 517 519 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 573 574 573 574 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 590 592 590 592 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 680 681 680 681 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 683 684 683 684 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 701 703 701 703 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 844 845 844 845 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 847 849 847 849 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 937 938 937 938 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 940 942 940 942 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 1314 1315 1314 1315 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 1317 1318 1317 1318 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 1603 1604 1603 1604 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 1606 1608 1606 1608 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 1690 1692 1690 1692 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 1694 1696 1694 1696 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 48 56 <span type="species:ncbi:9606">patients</span>
###xml 341 349 <span type="species:ncbi:9606">patients</span>
###xml 1170 1178 <span type="species:ncbi:9606">patients</span>
###xml 1469 1477 <span type="species:ncbi:9606">patients</span>
A direct analysis of coagulation factors in SAH patients is hampered by early activation of the coagulation and fibrinolytic system following the hemorrhage [21]. Therefore, studying genetic factors may be a better approach to investigate the role of coagulation factors in the development of complications after SAH. A genetic study in SAH patients already suggested that the plasminogen activator inhibitor-1 (PAI-1) gene influencing coagulation is indeed involved in the occurrence of secondary cerebral ischemia [30]. The role of polymorphisms in coagulation factor V [5], prothrombin [22], methylenetetetrahydrofolate reductase (MTHFR, 9), coagulation factor XIII subunit A [2, 3] and subunit B [18] genes is currently unclear. The factor V Leiden and prothrombin G20210A polymorphisms are associated with an increased risk of thrombosis [5, 22], and for the factor V Leiden a decreased risk of bleeding has also been demonstrated [7, 19]. The factor V Leiden and prothrombin G20210A polymorphisms may therefore be associated with a possible decreased risk of SAH, an increased risk of secondary cerebral ischemia and possibly a decreased risk of rebleeding in SAH patients. In contrast, subunit A Val34Leu, Tyr204Phe and Pro564Leu factor XIII polymorphisms are associated with an increased risk of bleeding [2, 3] and may increase the risk for aneurysmal SAH and its subsequent rebleeding, and possibly show a decreased risk of secondary cerebral ischemia in SAH patients. The role of the MTHFR C677T polymorphism and subunit B His95Arg factor XIII polymorphism in coagulation is not (yet) clear [9, 18], but some studies have found an increased risk of thrombosis for both variants [17, 18].
###end p 13
###begin p 14
###xml 191 199 <span type="species:ncbi:9606">patients</span>
The aim of this study was to investigate whether the above-mentioned polymorphisms are associated with the occurrence of aneurysmal SAH and with secondary cerebral ischemia and rebleeding in patients with aneurysmal SAH.
###end p 14
###begin title 15
Methods and materials
###end title 15
###begin title 16
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient and control recruitment
###end title 16
###begin p 17
###xml 507 509 507 509 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 24 32 <span type="species:ncbi:9606">patients</span>
###xml 351 356 <span type="species:ncbi:9606">women</span>
Two hundred eight Dutch patients with aneurysmal SAH admitted to the University Medical Centre Utrecht were included. Aneurysmal SAH was defined by symptoms suggestive of SAH combined with evidence of subarachnoid blood on CT and a proven aneurysm on CT angiography or conventional angiography. A population-based control group was used including 925 women aged 18-49 years without a history of coronary heart disease, cerebrovascular event or peripheral vascular disease, as described in detail elsewhere [29]. The ethical review board of the University Medical Centre Utrecht approved our study protocol.
###end p 17
###begin title 18
Data collection
###end title 18
###begin p 19
###xml 299 300 299 300 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 454 456 454 456 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 4 11 <span type="species:ncbi:9606">patient</span>
###xml 841 849 <span type="species:ncbi:9606">patients</span>
The patient's age at the time of SAH, sex, clinical condition on admission, amount of blood on initial CT scan, and any episodes of rebleeding or secondary cerebral ischemia were recorded. For the clinical condition on admission the World Federation of Neurological Surgeons' (WFNS) scale was used [8]. The amount of blood on the CT scan on admission (within 72 h after the initial symptoms) was graded on a scale of 0 to 30 as defined by Hijdra et al. [11]. Rebleeding was defined as a sudden deterioration in the level of consciousness or a sudden increase in headache, combined with an increase of blood on CT compared with the previous CT. Secondary cerebral ischemia was defined as a gradual decline in the level of consciousness or a gradual development of new focal deficits or both, with confirmation of a new hypodensity on CT. The patients were followed up for 3 months.
###end p 19
###begin title 20
Laboratory analyses
###end title 20
###begin p 21
###xml 204 205 204 205 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 229 231 229 231 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 247 248 247 248 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 271 273 271 273 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 313 315 313 315 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 353 355 353 355 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 446 454 <span type="species:ncbi:9606">patients</span>
DNA was isolated from whole venous blood. Genotyping was performed using polymerase chain reaction (PCR) using previously described primers and assay conditions for the factor V Leiden (factor V G1691A) [5], prothrombin G20210A [22], MTHFR C677T [9], subunit A Val34Leu [16], Tyr204Phe and Pro564Leu factor XIII [24] and subunit B His95Arg factor XIII [18] polymorphisms. Genotyping of the variants was performed on coded DNA samples so that the patients' characteristics remained unknown to the technician.
###end p 21
###begin title 22
Data analyses
###end title 22
###begin p 23
###xml 1223 1224 1223 1224 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 1226 1228 1226 1228 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 1230 1232 1230 1232 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 279 287 <span type="species:ncbi:9606">patients</span>
###xml 343 351 <span type="species:ncbi:9606">patients</span>
###xml 442 450 <span type="species:ncbi:9606">patients</span>
###xml 504 512 <span type="species:ncbi:9606">patients</span>
###xml 666 674 <span type="species:ncbi:9606">patients</span>
###xml 741 749 <span type="species:ncbi:9606">Patients</span>
The risk of aneurysmal SAH was assessed as an odds ratio (OR) with corresponding 95% confidence intervals (CI). The risk of secondary cerebral ischemia and rebleeding was assessed as a hazard ratio (HR) with 95% confidence intervals (CI) using Cox regression. For both analyses, patients homozygous for the wild-type allele were compared with patients homozygous and heterozygous for the variant allele. Only for the MTHFR C677T polymorphism patients homozygous for the variant allele were compared with patients homozygous for the wild-type allele and heterozygous for the variant allele, as customary. For the assessment of the risk of secondary cerebral ischemia patients were censored in case they had a rebleeding or in case they died. Patients were censored in the analysis on the risk of rebleeding in case the aneurysm was treated by means of clipping or coiling or in case they died. The clinical condition on admission was determined as 'good' (WFNS I-III) or 'poor' (WFNS IV-V). For the amount of cisternal blood, the scores were dichotomized at the median of the Hijdra scores. As a poor clinical condition on admission and a large amount of extravasated blood increase the risk of secondary cerebral ischemia [1, 12, 23], we adjusted for these prognostic factors using their dichotomized values.
###end p 23
###begin title 24
Results
###end title 24
###begin p 25
###xml 54 55 54 55 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 210 217 210 217 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 217 251 217 251 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="26">Patients&#8217; baseline characteristics</p>
###xml 217 251 217 251 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="26">Patients&#8217; baseline characteristics</p></caption>
###xml 251 266 251 266 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Characteristics</th>
###xml 266 288 266 288 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">All patients (n&#8201;=&#8201;208)</th>
###xml 251 288 251 288 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><th>Characteristics</th><th>All patients (n&#8201;=&#8201;208)</th></tr>
###xml 251 288 251 288 <thead xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>Characteristics</th><th>All patients (n&#8201;=&#8201;208)</th></tr></thead>
###xml 288 303 288 301 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Mean age &#177; SD</td>
###xml 303 316 301 312 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">59.5&#8201;&#177;&#8201;14.9</td>
###xml 288 316 288 312 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Mean age &#177; SD</td><td>59.5&#8201;&#177;&#8201;14.9</td></tr>
###xml 316 321 312 317 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Women</td>
###xml 321 332 317 328 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">149 (71.6%)</td>
###xml 316 332 312 328 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Women</td><td>149 (71.6%)</td></tr>
###xml 332 368 328 364 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Poor clinical condition on admission</td>
###xml 368 378 364 374 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">41 (19.7%)</td>
###xml 332 378 328 374 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Poor clinical condition on admission</td><td>41 (19.7%)</td></tr>
###xml 378 432 374 428 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Amount of cisternal blood &gt; median of the Hijdra score</td>
###xml 432 442 428 438 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">74 (35.6%)</td>
###xml 378 442 374 438 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Amount of cisternal blood &gt; median of the Hijdra score</td><td>74 (35.6%)</td></tr>
###xml 442 452 438 448 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Rebleeding</td>
###xml 452 462 448 458 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">28 (13.5%)</td>
###xml 442 462 438 458 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Rebleeding</td><td>28 (13.5%)</td></tr>
###xml 462 489 458 485 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Secondary cerebral ischemia</td>
###xml 489 499 485 495 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">49 (23.6%)</td>
###xml 462 499 458 495 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Secondary cerebral ischemia</td><td>49 (23.6%)</td></tr>
###xml 288 499 288 495 <tbody xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>Mean age &#177; SD</td><td>59.5&#8201;&#177;&#8201;14.9</td></tr><tr><td>Women</td><td>149 (71.6%)</td></tr><tr><td>Poor clinical condition on admission</td><td>41 (19.7%)</td></tr><tr><td>Amount of cisternal blood &gt; median of the Hijdra score</td><td>74 (35.6%)</td></tr><tr><td>Rebleeding</td><td>28 (13.5%)</td></tr><tr><td>Secondary cerebral ischemia</td><td>49 (23.6%)</td></tr></tbody>
###xml 251 499 251 495 <table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>Characteristics</th><th>All patients (n&#8201;=&#8201;208)</th></tr></thead><tbody><tr><td>Mean age &#177; SD</td><td>59.5&#8201;&#177;&#8201;14.9</td></tr><tr><td>Women</td><td>149 (71.6%)</td></tr><tr><td>Poor clinical condition on admission</td><td>41 (19.7%)</td></tr><tr><td>Amount of cisternal blood &gt; median of the Hijdra score</td><td>74 (35.6%)</td></tr><tr><td>Rebleeding</td><td>28 (13.5%)</td></tr><tr><td>Secondary cerebral ischemia</td><td>49 (23.6%)</td></tr></tbody></table>
###xml 499 522 495 518 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="27">SD = standard deviation</p>
###xml 499 522 495 518 <table-wrap-foot xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="27">SD = standard deviation</p></table-wrap-foot>
###xml 210 522 210 518 <table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="26">Patients&#8217; baseline characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Characteristics</th><th>All patients (n&#8201;=&#8201;208)</th></tr></thead><tbody><tr><td>Mean age &#177; SD</td><td>59.5&#8201;&#177;&#8201;14.9</td></tr><tr><td>Women</td><td>149 (71.6%)</td></tr><tr><td>Poor clinical condition on admission</td><td>41 (19.7%)</td></tr><tr><td>Amount of cisternal blood &gt; median of the Hijdra score</td><td>74 (35.6%)</td></tr><tr><td>Rebleeding</td><td>28 (13.5%)</td></tr><tr><td>Secondary cerebral ischemia</td><td>49 (23.6%)</td></tr></tbody></table><table-wrap-foot><p textid="27">SD = standard deviation</p></table-wrap-foot></table-wrap>
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 117 122 <span type="species:ncbi:9606">women</span>
###xml 173 181 <span type="species:ncbi:9606">patients</span>
###xml 270 278 <span type="species:ncbi:9606">patients</span>
The patients' characteristics are summarized in Table 1. The mean age was 59.5 years (SD 14.9 years), and 71.6% were women. Secondary cerebral ischemia occurred in 49 (24%) patients and rebleeding in 28 (14%). Table 1Patients' baseline characteristicsCharacteristicsAll patients (n = 208)Mean age +/- SD59.5 +/- 14.9Women149 (71.6%)Poor clinical condition on admission41 (19.7%)Amount of cisternal blood > median of the Hijdra score74 (35.6%)Rebleeding28 (13.5%)Secondary cerebral ischemia49 (23.6%)SD = standard deviation
###end p 25
###begin p 26
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients' baseline characteristics
###end p 26
###begin p 27
SD = standard deviation
###end p 27
###begin p 28
###xml 80 81 80 81 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 715 722 715 722 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 722 802 722 802 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="29">Odds ratios for risk of aneurysmal subarachnoid hemorrhage according to genotype</p>
###xml 722 802 722 802 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="29">Odds ratios for risk of aneurysmal subarachnoid hemorrhage according to genotype</p></caption>
###xml 802 810 802 810 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Genotype</th>
###xml 810 819 810 819 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Patients*</th>
###xml 819 829 819 829 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Controls**</th>
###xml 829 848 829 848 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Odds ratio (95% CI)</th>
###xml 802 848 802 848 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><th>Genotype</th><th>Patients*</th><th>Controls**</th><th>Odds ratio (95% CI)</th></tr>
###xml 802 848 802 848 <thead xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>Genotype</th><th>Patients*</th><th>Controls**</th><th>Odds ratio (95% CI)</th></tr></thead>
###xml 848 857 848 857 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">FV Leiden</td>
###xml 857 864 857 864 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n&#8201;=&#8201;207</td>
###xml 864 871 864 871 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n&#8201;=&#8201;763</td>
###xml 871 871 871 871 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 848 871 848 871 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>FV Leiden</td><td>n&#8201;=&#8201;207</td><td>n&#8201;=&#8201;763</td><td/></tr>
###xml 871 874 871 874 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;GG</td>
###xml 874 885 874 885 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">196 (94.7%)</td>
###xml 885 896 885 896 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">721 (94.5%)</td>
###xml 896 909 896 909 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1 (reference)</td>
###xml 871 909 871 909 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;GG</td><td>196 (94.7%)</td><td>721 (94.5%)</td><td>1 (reference)</td></tr>
###xml 909 919 909 919 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;GA and AA</td>
###xml 919 928 919 928 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">11 (5.3%)</td>
###xml 928 937 928 937 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">42 (5.5%)</td>
###xml 937 950 937 950 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0.9 (0.5&#8211;1.8)</td>
###xml 909 950 909 950 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;GA and AA</td><td>11 (5.3%)</td><td>42 (5.5%)</td><td>0.9 (0.5&#8211;1.8)</td></tr>
###xml 950 969 950 969 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Prothrombin G20210A</td>
###xml 969 976 969 976 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n&#8201;=&#8201;207</td>
###xml 976 983 976 983 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n&#8201;=&#8201;763</td>
###xml 983 983 983 983 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 950 983 950 983 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Prothrombin G20210A</td><td>n&#8201;=&#8201;207</td><td>n&#8201;=&#8201;763</td><td/></tr>
###xml 983 986 983 986 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;GG</td>
###xml 986 997 986 997 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">200 (96.6%)</td>
###xml 997 1008 997 1008 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">745 (97.6%)</td>
###xml 1008 1021 1008 1021 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1 (reference)</td>
###xml 983 1021 983 1021 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;GG</td><td>200 (96.6%)</td><td>745 (97.6%)</td><td>1 (reference)</td></tr>
###xml 1021 1031 1021 1031 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;GA and AA</td>
###xml 1031 1039 1031 1039 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">7 (3.4%)</td>
###xml 1039 1048 1039 1048 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">18 (2.4%)</td>
###xml 1048 1061 1048 1061 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1.5 (0.6&#8211;3.5)</td>
###xml 1021 1061 1021 1061 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;GA and AA</td><td>7 (3.4%)</td><td>18 (2.4%)</td><td>1.5 (0.6&#8211;3.5)</td></tr>
###xml 1061 1072 1061 1072 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR C677T</td>
###xml 1072 1079 1072 1079 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n&#8201;=&#8201;207</td>
###xml 1079 1086 1079 1086 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n&#8201;=&#8201;764</td>
###xml 1086 1086 1086 1086 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1061 1086 1061 1086 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>MTHFR C677T</td><td>n&#8201;=&#8201;207</td><td>n&#8201;=&#8201;764</td><td/></tr>
###xml 1086 1096 1086 1096 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;CC and CT</td>
###xml 1096 1107 1096 1107 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">185 (89.4%)</td>
###xml 1107 1118 1107 1118 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">695 (91.0%)</td>
###xml 1118 1131 1118 1131 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1 (reference)</td>
###xml 1086 1131 1086 1131 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;CC and CT</td><td>185 (89.4%)</td><td>695 (91.0%)</td><td>1 (reference)</td></tr>
###xml 1131 1134 1131 1134 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;TT</td>
###xml 1134 1144 1134 1144 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">22 (10.6%)</td>
###xml 1144 1153 1144 1153 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">69 (9.0%)</td>
###xml 1153 1166 1153 1166 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1.2 (0.3&#8211;2.0)</td>
###xml 1131 1166 1131 1166 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;TT</td><td>22 (10.6%)</td><td>69 (9.0%)</td><td>1.2 (0.3&#8211;2.0)</td></tr>
###xml 1166 1182 1166 1182 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">FXIII A Val34Leu</td>
###xml 1182 1189 1182 1189 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n&#8201;=&#8201;208</td>
###xml 1189 1196 1189 1196 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n&#8201;=&#8201;747</td>
###xml 1196 1196 1196 1196 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1166 1196 1166 1196 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>FXIII A Val34Leu</td><td>n&#8201;=&#8201;208</td><td>n&#8201;=&#8201;747</td><td/></tr>
###xml 1196 1203 1196 1203 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;ValVal</td>
###xml 1203 1214 1203 1214 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">122 (58.7%)</td>
###xml 1214 1225 1214 1225 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">419 (56.1%)</td>
###xml 1225 1238 1225 1238 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1 (reference)</td>
###xml 1196 1238 1196 1238 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;ValVal</td><td>122 (58.7%)</td><td>419 (56.1%)</td><td>1 (reference)</td></tr>
###xml 1238 1256 1238 1256 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;ValLeu and LeuLeu</td>
###xml 1256 1266 1256 1266 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">86 (41.3%)</td>
###xml 1266 1277 1266 1277 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">328 (43.9%)</td>
###xml 1277 1290 1277 1290 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0.9 (0.7&#8211;1.2)</td>
###xml 1238 1290 1238 1290 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;ValLeu and LeuLeu</td><td>86 (41.3%)</td><td>328 (43.9%)</td><td>0.9 (0.7&#8211;1.2)</td></tr>
###xml 1290 1307 1290 1307 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">FXIII A Tyr204Phe</td>
###xml 1307 1314 1307 1314 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n&#8201;=&#8201;207</td>
###xml 1314 1321 1314 1321 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n&#8201;=&#8201;754</td>
###xml 1321 1321 1321 1321 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1290 1321 1290 1321 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>FXIII A Tyr204Phe</td><td>n&#8201;=&#8201;207</td><td>n&#8201;=&#8201;754</td><td/></tr>
###xml 1321 1328 1321 1328 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;TyrTyr</td>
###xml 1328 1339 1328 1339 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">188 (90.8%)</td>
###xml 1339 1350 1339 1350 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">711 (94.3%)</td>
###xml 1350 1363 1350 1363 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1 (reference)</td>
###xml 1321 1363 1321 1363 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;TyrTyr</td><td>188 (90.8%)</td><td>711 (94.3%)</td><td>1 (reference)</td></tr>
###xml 1363 1381 1363 1381 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;TyrPhe and PhePhe</td>
###xml 1381 1390 1381 1390 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">19 (9.2%)</td>
###xml 1390 1399 1390 1399 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">43 (5.7%)</td>
###xml 1399 1412 1399 1412 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1.7 (0.9&#8211;2.9)</td>
###xml 1363 1412 1363 1412 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;TyrPhe and PhePhe</td><td>19 (9.2%)</td><td>43 (5.7%)</td><td>1.7 (0.9&#8211;2.9)</td></tr>
###xml 1412 1429 1412 1429 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">FXIII A Pro564Leu</td>
###xml 1429 1436 1429 1436 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n&#8201;=&#8201;194</td>
###xml 1436 1443 1436 1443 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n&#8201;=&#8201;751</td>
###xml 1443 1443 1443 1443 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1412 1443 1412 1443 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>FXIII A Pro564Leu</td><td>n&#8201;=&#8201;194</td><td>n&#8201;=&#8201;751</td><td/></tr>
###xml 1443 1450 1443 1450 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;ProPro</td>
###xml 1450 1461 1450 1461 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">114 (58.8%)</td>
###xml 1461 1472 1461 1472 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">466 (62.0%)</td>
###xml 1472 1485 1472 1485 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1 (reference)</td>
###xml 1443 1485 1443 1485 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;ProPro</td><td>114 (58.8%)</td><td>466 (62.0%)</td><td>1 (reference)</td></tr>
###xml 1485 1503 1485 1503 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;ProLeu and LeuLeu</td>
###xml 1503 1513 1503 1513 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">80 (41.2%)</td>
###xml 1513 1524 1513 1524 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">285 (38.0%)</td>
###xml 1524 1537 1524 1537 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1.2 (0.8&#8211;1.6)</td>
###xml 1485 1537 1485 1537 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;ProLeu and LeuLeu</td><td>80 (41.2%)</td><td>285 (38.0%)</td><td>1.2 (0.8&#8211;1.6)</td></tr>
###xml 1537 1553 1537 1553 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">FXIII B His95Arg</td>
###xml 1553 1560 1553 1560 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n&#8201;=&#8201;196</td>
###xml 1560 1567 1560 1567 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">n&#8201;=&#8201;730</td>
###xml 1567 1567 1567 1567 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1537 1567 1537 1567 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>FXIII B His95Arg</td><td>n&#8201;=&#8201;196</td><td>n&#8201;=&#8201;730</td><td/></tr>
###xml 1567 1574 1567 1574 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;HisHis</td>
###xml 1574 1585 1574 1585 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">151 (77.0%)</td>
###xml 1585 1596 1585 1596 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">609 (83.4%)</td>
###xml 1596 1609 1596 1609 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1 (reference)</td>
###xml 1567 1609 1567 1609 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;HisHis</td><td>151 (77.0%)</td><td>609 (83.4%)</td><td>1 (reference)</td></tr>
###xml 1609 1627 1609 1627 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;HisArg and ArgArg</td>
###xml 1627 1637 1627 1637 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">45 (23.0%)</td>
###xml 1637 1648 1637 1648 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">121 (16.6%)</td>
###xml 1648 1661 1648 1661 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1.5 (1.0&#8211;2.2)</td>
###xml 1609 1661 1609 1661 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;HisArg and ArgArg</td><td>45 (23.0%)</td><td>121 (16.6%)</td><td>1.5 (1.0&#8211;2.2)</td></tr>
###xml 848 1661 848 1661 <tbody xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>FV Leiden</td><td>n&#8201;=&#8201;207</td><td>n&#8201;=&#8201;763</td><td/></tr><tr><td>&#160;GG</td><td>196 (94.7%)</td><td>721 (94.5%)</td><td>1 (reference)</td></tr><tr><td>&#160;GA and AA</td><td>11 (5.3%)</td><td>42 (5.5%)</td><td>0.9 (0.5&#8211;1.8)</td></tr><tr><td>Prothrombin G20210A</td><td>n&#8201;=&#8201;207</td><td>n&#8201;=&#8201;763</td><td/></tr><tr><td>&#160;GG</td><td>200 (96.6%)</td><td>745 (97.6%)</td><td>1 (reference)</td></tr><tr><td>&#160;GA and AA</td><td>7 (3.4%)</td><td>18 (2.4%)</td><td>1.5 (0.6&#8211;3.5)</td></tr><tr><td>MTHFR C677T</td><td>n&#8201;=&#8201;207</td><td>n&#8201;=&#8201;764</td><td/></tr><tr><td>&#160;CC and CT</td><td>185 (89.4%)</td><td>695 (91.0%)</td><td>1 (reference)</td></tr><tr><td>&#160;TT</td><td>22 (10.6%)</td><td>69 (9.0%)</td><td>1.2 (0.3&#8211;2.0)</td></tr><tr><td>FXIII A Val34Leu</td><td>n&#8201;=&#8201;208</td><td>n&#8201;=&#8201;747</td><td/></tr><tr><td>&#160;ValVal</td><td>122 (58.7%)</td><td>419 (56.1%)</td><td>1 (reference)</td></tr><tr><td>&#160;ValLeu and LeuLeu</td><td>86 (41.3%)</td><td>328 (43.9%)</td><td>0.9 (0.7&#8211;1.2)</td></tr><tr><td>FXIII A Tyr204Phe</td><td>n&#8201;=&#8201;207</td><td>n&#8201;=&#8201;754</td><td/></tr><tr><td>&#160;TyrTyr</td><td>188 (90.8%)</td><td>711 (94.3%)</td><td>1 (reference)</td></tr><tr><td>&#160;TyrPhe and PhePhe</td><td>19 (9.2%)</td><td>43 (5.7%)</td><td>1.7 (0.9&#8211;2.9)</td></tr><tr><td>FXIII A Pro564Leu</td><td>n&#8201;=&#8201;194</td><td>n&#8201;=&#8201;751</td><td/></tr><tr><td>&#160;ProPro</td><td>114 (58.8%)</td><td>466 (62.0%)</td><td>1 (reference)</td></tr><tr><td>&#160;ProLeu and LeuLeu</td><td>80 (41.2%)</td><td>285 (38.0%)</td><td>1.2 (0.8&#8211;1.6)</td></tr><tr><td>FXIII B His95Arg</td><td>n&#8201;=&#8201;196</td><td>n&#8201;=&#8201;730</td><td/></tr><tr><td>&#160;HisHis</td><td>151 (77.0%)</td><td>609 (83.4%)</td><td>1 (reference)</td></tr><tr><td>&#160;HisArg and ArgArg</td><td>45 (23.0%)</td><td>121 (16.6%)</td><td>1.5 (1.0&#8211;2.2)</td></tr></tbody>
###xml 802 1661 802 1661 <table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>Genotype</th><th>Patients*</th><th>Controls**</th><th>Odds ratio (95% CI)</th></tr></thead><tbody><tr><td>FV Leiden</td><td>n&#8201;=&#8201;207</td><td>n&#8201;=&#8201;763</td><td/></tr><tr><td>&#160;GG</td><td>196 (94.7%)</td><td>721 (94.5%)</td><td>1 (reference)</td></tr><tr><td>&#160;GA and AA</td><td>11 (5.3%)</td><td>42 (5.5%)</td><td>0.9 (0.5&#8211;1.8)</td></tr><tr><td>Prothrombin G20210A</td><td>n&#8201;=&#8201;207</td><td>n&#8201;=&#8201;763</td><td/></tr><tr><td>&#160;GG</td><td>200 (96.6%)</td><td>745 (97.6%)</td><td>1 (reference)</td></tr><tr><td>&#160;GA and AA</td><td>7 (3.4%)</td><td>18 (2.4%)</td><td>1.5 (0.6&#8211;3.5)</td></tr><tr><td>MTHFR C677T</td><td>n&#8201;=&#8201;207</td><td>n&#8201;=&#8201;764</td><td/></tr><tr><td>&#160;CC and CT</td><td>185 (89.4%)</td><td>695 (91.0%)</td><td>1 (reference)</td></tr><tr><td>&#160;TT</td><td>22 (10.6%)</td><td>69 (9.0%)</td><td>1.2 (0.3&#8211;2.0)</td></tr><tr><td>FXIII A Val34Leu</td><td>n&#8201;=&#8201;208</td><td>n&#8201;=&#8201;747</td><td/></tr><tr><td>&#160;ValVal</td><td>122 (58.7%)</td><td>419 (56.1%)</td><td>1 (reference)</td></tr><tr><td>&#160;ValLeu and LeuLeu</td><td>86 (41.3%)</td><td>328 (43.9%)</td><td>0.9 (0.7&#8211;1.2)</td></tr><tr><td>FXIII A Tyr204Phe</td><td>n&#8201;=&#8201;207</td><td>n&#8201;=&#8201;754</td><td/></tr><tr><td>&#160;TyrTyr</td><td>188 (90.8%)</td><td>711 (94.3%)</td><td>1 (reference)</td></tr><tr><td>&#160;TyrPhe and PhePhe</td><td>19 (9.2%)</td><td>43 (5.7%)</td><td>1.7 (0.9&#8211;2.9)</td></tr><tr><td>FXIII A Pro564Leu</td><td>n&#8201;=&#8201;194</td><td>n&#8201;=&#8201;751</td><td/></tr><tr><td>&#160;ProPro</td><td>114 (58.8%)</td><td>466 (62.0%)</td><td>1 (reference)</td></tr><tr><td>&#160;ProLeu and LeuLeu</td><td>80 (41.2%)</td><td>285 (38.0%)</td><td>1.2 (0.8&#8211;1.6)</td></tr><tr><td>FXIII B His95Arg</td><td>n&#8201;=&#8201;196</td><td>n&#8201;=&#8201;730</td><td/></tr><tr><td>&#160;HisHis</td><td>151 (77.0%)</td><td>609 (83.4%)</td><td>1 (reference)</td></tr><tr><td>&#160;HisArg and ArgArg</td><td>45 (23.0%)</td><td>121 (16.6%)</td><td>1.5 (1.0&#8211;2.2)</td></tr></tbody></table>
###xml 1661 1745 1661 1745 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="30">*For the genotype analysis of the patients the percentage of missing genotypes is 2%</p>
###xml 1745 1831 1745 1831 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="31">**For the genotype analysis of the controls the percentage of missing genotypes is 18%</p>
###xml 1831 1855 1831 1855 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="32">CI = confidence interval</p>
###xml 1661 1855 1661 1855 <table-wrap-foot xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="30">*For the genotype analysis of the patients the percentage of missing genotypes is 2%</p><p textid="31">**For the genotype analysis of the controls the percentage of missing genotypes is 18%</p><p textid="32">CI = confidence interval</p></table-wrap-foot>
###xml 715 1855 715 1855 <table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="29">Odds ratios for risk of aneurysmal subarachnoid hemorrhage according to genotype</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Genotype</th><th>Patients*</th><th>Controls**</th><th>Odds ratio (95% CI)</th></tr></thead><tbody><tr><td>FV Leiden</td><td>n&#8201;=&#8201;207</td><td>n&#8201;=&#8201;763</td><td/></tr><tr><td>&#160;GG</td><td>196 (94.7%)</td><td>721 (94.5%)</td><td>1 (reference)</td></tr><tr><td>&#160;GA and AA</td><td>11 (5.3%)</td><td>42 (5.5%)</td><td>0.9 (0.5&#8211;1.8)</td></tr><tr><td>Prothrombin G20210A</td><td>n&#8201;=&#8201;207</td><td>n&#8201;=&#8201;763</td><td/></tr><tr><td>&#160;GG</td><td>200 (96.6%)</td><td>745 (97.6%)</td><td>1 (reference)</td></tr><tr><td>&#160;GA and AA</td><td>7 (3.4%)</td><td>18 (2.4%)</td><td>1.5 (0.6&#8211;3.5)</td></tr><tr><td>MTHFR C677T</td><td>n&#8201;=&#8201;207</td><td>n&#8201;=&#8201;764</td><td/></tr><tr><td>&#160;CC and CT</td><td>185 (89.4%)</td><td>695 (91.0%)</td><td>1 (reference)</td></tr><tr><td>&#160;TT</td><td>22 (10.6%)</td><td>69 (9.0%)</td><td>1.2 (0.3&#8211;2.0)</td></tr><tr><td>FXIII A Val34Leu</td><td>n&#8201;=&#8201;208</td><td>n&#8201;=&#8201;747</td><td/></tr><tr><td>&#160;ValVal</td><td>122 (58.7%)</td><td>419 (56.1%)</td><td>1 (reference)</td></tr><tr><td>&#160;ValLeu and LeuLeu</td><td>86 (41.3%)</td><td>328 (43.9%)</td><td>0.9 (0.7&#8211;1.2)</td></tr><tr><td>FXIII A Tyr204Phe</td><td>n&#8201;=&#8201;207</td><td>n&#8201;=&#8201;754</td><td/></tr><tr><td>&#160;TyrTyr</td><td>188 (90.8%)</td><td>711 (94.3%)</td><td>1 (reference)</td></tr><tr><td>&#160;TyrPhe and PhePhe</td><td>19 (9.2%)</td><td>43 (5.7%)</td><td>1.7 (0.9&#8211;2.9)</td></tr><tr><td>FXIII A Pro564Leu</td><td>n&#8201;=&#8201;194</td><td>n&#8201;=&#8201;751</td><td/></tr><tr><td>&#160;ProPro</td><td>114 (58.8%)</td><td>466 (62.0%)</td><td>1 (reference)</td></tr><tr><td>&#160;ProLeu and LeuLeu</td><td>80 (41.2%)</td><td>285 (38.0%)</td><td>1.2 (0.8&#8211;1.6)</td></tr><tr><td>FXIII B His95Arg</td><td>n&#8201;=&#8201;196</td><td>n&#8201;=&#8201;730</td><td/></tr><tr><td>&#160;HisHis</td><td>151 (77.0%)</td><td>609 (83.4%)</td><td>1 (reference)</td></tr><tr><td>&#160;HisArg and ArgArg</td><td>45 (23.0%)</td><td>121 (16.6%)</td><td>1.5 (1.0&#8211;2.2)</td></tr></tbody></table><table-wrap-foot><p textid="30">*For the genotype analysis of the patients the percentage of missing genotypes is 2%</p><p textid="31">**For the genotype analysis of the controls the percentage of missing genotypes is 18%</p><p textid="32">CI = confidence interval</p></table-wrap-foot></table-wrap>
###xml 210 218 <span type="species:ncbi:9606">patients</span>
###xml 1695 1703 <span type="species:ncbi:9606">patients</span>
The ORs for the risk of aneurysmal SAH according to genotype are shown in Table 2. For carriers of the subunit B His95Arg factor XIII polymorphism, an increased risk of aneurysmal SAH was found with 23% of the patients homozygous and heterozygous for the variant allele compared to 17% of control subjects (OR 1.5, 95% CI 1.0-2.2, p-value 0.04). Also, carriers of the prothrombin G20210A and the subunit Tyr204Phe factor XIII polymorphisms showed an increased risk of aneurysmal SAH, but these differences did not reach statistical significance. Carriers of the factor V Leiden (factor V G1691A), MTHFR C677T, subunit A Val34Leu and Pro564Leu factor XIII polymorphisms did not have a higher risk of aneurysmal SAH. Table 2Odds ratios for risk of aneurysmal subarachnoid hemorrhage according to genotypeGenotypePatients*Controls**Odds ratio (95% CI)FV Leidenn = 207n = 763 GG196 (94.7%)721 (94.5%)1 (reference) GA and AA11 (5.3%)42 (5.5%)0.9 (0.5-1.8)Prothrombin G20210An = 207n = 763 GG200 (96.6%)745 (97.6%)1 (reference) GA and AA7 (3.4%)18 (2.4%)1.5 (0.6-3.5)MTHFR C677Tn = 207n = 764 CC and CT185 (89.4%)695 (91.0%)1 (reference) TT22 (10.6%)69 (9.0%)1.2 (0.3-2.0)FXIII A Val34Leun = 208n = 747 ValVal122 (58.7%)419 (56.1%)1 (reference) ValLeu and LeuLeu86 (41.3%)328 (43.9%)0.9 (0.7-1.2)FXIII A Tyr204Phen = 207n = 754 TyrTyr188 (90.8%)711 (94.3%)1 (reference) TyrPhe and PhePhe19 (9.2%)43 (5.7%)1.7 (0.9-2.9)FXIII A Pro564Leun = 194n = 751 ProPro114 (58.8%)466 (62.0%)1 (reference) ProLeu and LeuLeu80 (41.2%)285 (38.0%)1.2 (0.8-1.6)FXIII B His95Argn = 196n = 730 HisHis151 (77.0%)609 (83.4%)1 (reference) HisArg and ArgArg45 (23.0%)121 (16.6%)1.5 (1.0-2.2)*For the genotype analysis of the patients the percentage of missing genotypes is 2%**For the genotype analysis of the controls the percentage of missing genotypes is 18%CI = confidence interval
###end p 28
###begin p 29
Odds ratios for risk of aneurysmal subarachnoid hemorrhage according to genotype
###end p 29
###begin p 30
###xml 34 42 <span type="species:ncbi:9606">patients</span>
*For the genotype analysis of the patients the percentage of missing genotypes is 2%
###end p 30
###begin p 31
**For the genotype analysis of the controls the percentage of missing genotypes is 18%
###end p 31
###begin p 32
CI = confidence interval
###end p 32
###begin p 33
###xml 6 7 6 7 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 488 489 488 489 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 748 755 748 755 <label xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;3</label>
###xml 755 886 755 886 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="34">Hazard ratios for risk of secondary cerebral ischemia and rebleeding after aneurysmal subarachnoid hemorrhage according to genotype</p>
###xml 755 886 755 886 <caption xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="34">Hazard ratios for risk of secondary cerebral ischemia and rebleeding after aneurysmal subarachnoid hemorrhage according to genotype</p></caption>
###xml 886 894 886 894 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Genotype</th>
###xml 894 906 894 906 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Complication</th>
###xml 906 921 906 921 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">No complication</th>
###xml 921 948 921 948 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Crude hazard ratio (95% CI)</th>
###xml 948 979 948 979 <th xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Adjusted hazard ratio (95% CI)*</th>
###xml 886 979 886 979 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><th>Genotype</th><th>Complication</th><th>No complication</th><th>Crude hazard ratio (95% CI)</th><th>Adjusted hazard ratio (95% CI)*</th></tr>
###xml 886 979 886 979 <thead xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>Genotype</th><th>Complication</th><th>No complication</th><th>Crude hazard ratio (95% CI)</th><th>Adjusted hazard ratio (95% CI)*</th></tr></thead>
###xml 979 988 979 988 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">FV Leiden</td>
###xml 988 1015 988 1015 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Secondary cerebral ischemia</td>
###xml 1015 1045 1015 1045 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">No secondary cerebral ischemia</td>
###xml 1045 1045 1045 1045 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1045 1045 1045 1045 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 979 1045 979 1045 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>FV Leiden</td><td>Secondary cerebral ischemia</td><td>No secondary cerebral ischemia</td><td/><td/></tr>
###xml 1045 1048 1045 1048 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;GG</td>
###xml 1048 1058 1048 1058 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">45 (23.0%)</td>
###xml 1058 1069 1058 1069 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">151 (77.0%)</td>
###xml 1069 1082 1069 1082 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1 (reference)</td>
###xml 1082 1095 1082 1095 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1 (reference)</td>
###xml 1045 1095 1045 1095 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;GG</td><td>45 (23.0%)</td><td>151 (77.0%)</td><td>1 (reference)</td><td>1 (reference)</td></tr>
###xml 1095 1105 1095 1105 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;GA and AA</td>
###xml 1105 1114 1105 1114 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">4 (36.4%)</td>
###xml 1114 1123 1114 1123 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">7 (63.6%)</td>
###xml 1123 1136 1123 1136 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1.8 (0.6&#8211;4.9)</td>
###xml 1136 1149 1136 1149 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1.8 (0.6&#8211;5.0)</td>
###xml 1095 1149 1095 1149 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;GA and AA</td><td>4 (36.4%)</td><td>7 (63.6%)</td><td>1.8 (0.6&#8211;4.9)</td><td>1.8 (0.6&#8211;5.0)</td></tr>
###xml 1149 1149 1149 1149 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1149 1159 1149 1159 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Rebleeding</td>
###xml 1159 1172 1159 1172 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">No rebleeding</td>
###xml 1172 1172 1172 1172 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1172 1172 1172 1172 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1149 1172 1149 1172 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td/><td>Rebleeding</td><td>No rebleeding</td><td/><td/></tr>
###xml 1172 1175 1172 1175 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;GG</td>
###xml 1175 1185 1175 1185 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">26 (13.2%)</td>
###xml 1185 1196 1185 1196 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">171 (86.8%)</td>
###xml 1196 1209 1196 1209 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1 (reference)</td>
###xml 1209 1209 1209 1209 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1172 1209 1172 1209 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;GG</td><td>26 (13.2%)</td><td>171 (86.8%)</td><td>1 (reference)</td><td/></tr>
###xml 1209 1219 1209 1219 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;GA and AA</td>
###xml 1219 1227 1219 1227 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1 (9.1%)</td>
###xml 1227 1237 1227 1237 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">10 (90.9%)</td>
###xml 1237 1250 1237 1250 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0.6 (0.1&#8211;4.5)</td>
###xml 1250 1252 1250 1252 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NA</td>
###xml 1209 1252 1209 1252 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;GA and AA</td><td>1 (9.1%)</td><td>10 (90.9%)</td><td>0.6 (0.1&#8211;4.5)</td><td>NA</td></tr>
###xml 1252 1271 1252 1271 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Prothrombin G20210A</td>
###xml 1271 1298 1271 1298 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Secondary cerebral ischemia</td>
###xml 1298 1328 1298 1328 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">No secondary cerebral ischemia</td>
###xml 1328 1328 1328 1328 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1328 1328 1328 1328 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1252 1328 1252 1328 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>Prothrombin G20210A</td><td>Secondary cerebral ischemia</td><td>No secondary cerebral ischemia</td><td/><td/></tr>
###xml 1328 1331 1328 1331 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;GG</td>
###xml 1331 1341 1331 1341 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">48 (24.0%)</td>
###xml 1341 1352 1341 1352 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">152 (76.0%)</td>
###xml 1352 1365 1352 1365 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1 (reference)</td>
###xml 1365 1378 1365 1378 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1 (reference)</td>
###xml 1328 1378 1328 1378 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;GG</td><td>48 (24.0%)</td><td>152 (76.0%)</td><td>1 (reference)</td><td>1 (reference)</td></tr>
###xml 1378 1388 1378 1388 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;GA and AA</td>
###xml 1388 1397 1388 1397 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1 (14.3%)</td>
###xml 1397 1406 1397 1406 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">6 (85.7%)</td>
###xml 1406 1419 1406 1419 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0.5 (0.1&#8211;3.9)</td>
###xml 1419 1432 1419 1432 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0.5 (0.1&#8211;3.9)</td>
###xml 1378 1432 1378 1432 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;GA and AA</td><td>1 (14.3%)</td><td>6 (85.7%)</td><td>0.5 (0.1&#8211;3.9)</td><td>0.5 (0.1&#8211;3.9)</td></tr>
###xml 1432 1432 1432 1432 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1432 1442 1432 1442 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Rebleeding</td>
###xml 1442 1455 1442 1455 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">No rebleeding</td>
###xml 1455 1455 1455 1455 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1455 1455 1455 1455 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1432 1455 1432 1455 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td/><td>Rebleeding</td><td>No rebleeding</td><td/><td/></tr>
###xml 1455 1458 1455 1458 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;GG</td>
###xml 1458 1468 1458 1468 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">27 (13.4%)</td>
###xml 1468 1479 1468 1479 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">174 (86.6%)</td>
###xml 1479 1492 1479 1492 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1 (reference)</td>
###xml 1492 1492 1492 1492 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1455 1492 1455 1492 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;GG</td><td>27 (13.4%)</td><td>174 (86.6%)</td><td>1 (reference)</td><td/></tr>
###xml 1492 1502 1492 1502 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;GA and AA</td>
###xml 1502 1508 1502 1508 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0 (0%)</td>
###xml 1508 1516 1508 1516 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">7 (100%)</td>
###xml 1516 1529 1516 1529 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0.7 (0.1&#8211;5.4)</td>
###xml 1529 1531 1529 1531 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NA</td>
###xml 1492 1531 1492 1531 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;GA and AA</td><td>0 (0%)</td><td>7 (100%)</td><td>0.7 (0.1&#8211;5.4)</td><td>NA</td></tr>
###xml 1531 1542 1531 1542 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">MTHFR C677T</td>
###xml 1542 1569 1542 1569 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Secondary cerebral ischemia</td>
###xml 1569 1599 1569 1599 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">No secondary cerebral ischemia</td>
###xml 1599 1599 1599 1599 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1599 1599 1599 1599 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1531 1599 1531 1599 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>MTHFR C677T</td><td>Secondary cerebral ischemia</td><td>No secondary cerebral ischemia</td><td/><td/></tr>
###xml 1599 1609 1599 1609 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;CC and CT</td>
###xml 1609 1619 1609 1619 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">47 (25.4%)</td>
###xml 1619 1630 1619 1630 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">138 (74.6%)</td>
###xml 1630 1643 1630 1643 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1 (reference)</td>
###xml 1643 1656 1643 1656 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1 (reference)</td>
###xml 1599 1656 1599 1656 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;CC and CT</td><td>47 (25.4%)</td><td>138 (74.6%)</td><td>1 (reference)</td><td>1 (reference)</td></tr>
###xml 1656 1659 1656 1659 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;TT</td>
###xml 1659 1667 1659 1667 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">2 (9.1%)</td>
###xml 1667 1677 1667 1677 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">20 (90.9%)</td>
###xml 1677 1690 1677 1690 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0.4 (0.1&#8211;1.5)</td>
###xml 1690 1703 1690 1703 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0.4 (0.1&#8211;1.5)</td>
###xml 1656 1703 1656 1703 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;TT</td><td>2 (9.1%)</td><td>20 (90.9%)</td><td>0.4 (0.1&#8211;1.5)</td><td>0.4 (0.1&#8211;1.5)</td></tr>
###xml 1703 1703 1703 1703 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1703 1713 1703 1713 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Rebleeding</td>
###xml 1713 1726 1713 1726 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">No rebleeding</td>
###xml 1726 1726 1726 1726 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1726 1726 1726 1726 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1703 1726 1703 1726 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td/><td>Rebleeding</td><td>No rebleeding</td><td/><td/></tr>
###xml 1726 1736 1726 1736 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;CC and CT</td>
###xml 1736 1746 1736 1746 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">22 (11.9%)</td>
###xml 1746 1757 1746 1757 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">163 (88.1%)</td>
###xml 1757 1770 1757 1770 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1 (reference)</td>
###xml 1770 1770 1770 1770 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1726 1770 1726 1770 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;CC and CT</td><td>22 (11.9%)</td><td>163 (88.1%)</td><td>1 (reference)</td><td/></tr>
###xml 1770 1773 1770 1773 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;TT</td>
###xml 1773 1782 1773 1782 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">4 (18.2%)</td>
###xml 1782 1792 1782 1792 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">18 (81.8%)</td>
###xml 1792 1805 1792 1805 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0.6 (0.2&#8211;1.7)</td>
###xml 1805 1807 1805 1807 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NA</td>
###xml 1770 1807 1770 1807 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;TT</td><td>4 (18.2%)</td><td>18 (81.8%)</td><td>0.6 (0.2&#8211;1.7)</td><td>NA</td></tr>
###xml 1807 1823 1807 1823 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">FXIII A Val34Leu</td>
###xml 1823 1850 1823 1850 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Secondary cerebral ischemia</td>
###xml 1850 1880 1850 1880 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">No secondary cerebral ischemia</td>
###xml 1880 1880 1880 1880 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1880 1880 1880 1880 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1807 1880 1807 1880 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>FXIII A Val34Leu</td><td>Secondary cerebral ischemia</td><td>No secondary cerebral ischemia</td><td/><td/></tr>
###xml 1880 1887 1880 1887 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;ValVal</td>
###xml 1887 1898 1887 1898 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">30 (24.62%)</td>
###xml 1898 1908 1898 1908 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">92 (75.4%)</td>
###xml 1908 1921 1908 1921 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1 (reference)</td>
###xml 1921 1934 1921 1934 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1 (reference)</td>
###xml 1880 1934 1880 1934 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;ValVal</td><td>30 (24.62%)</td><td>92 (75.4%)</td><td>1 (reference)</td><td>1 (reference)</td></tr>
###xml 1934 1952 1934 1952 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;ValLeu and LeuLeu</td>
###xml 1952 1962 1952 1962 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">18 (20.9%)</td>
###xml 1962 1972 1962 1972 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">68 (79.1%)</td>
###xml 1972 1985 1972 1985 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0.9 (0.5&#8211;1.6)</td>
###xml 1985 1998 1985 1998 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0.9 (0.5&#8211;1.6)</td>
###xml 1934 1998 1934 1998 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;ValLeu and LeuLeu</td><td>18 (20.9%)</td><td>68 (79.1%)</td><td>0.9 (0.5&#8211;1.6)</td><td>0.9 (0.5&#8211;1.6)</td></tr>
###xml 1998 1998 1998 1998 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1998 2008 1998 2008 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Rebleeding</td>
###xml 2008 2021 2008 2021 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">No rebleeding</td>
###xml 2021 2021 2021 2021 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2021 2021 2021 2021 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1998 2021 1998 2021 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td/><td>Rebleeding</td><td>No rebleeding</td><td/><td/></tr>
###xml 2021 2028 2021 2028 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;ValVal</td>
###xml 2028 2038 2028 2038 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">14 (11.4%)</td>
###xml 2038 2049 2038 2049 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">109 (88.6%)</td>
###xml 2049 2062 2049 2062 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1 (reference)</td>
###xml 2062 2062 2062 2062 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2021 2062 2021 2062 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;ValVal</td><td>14 (11.4%)</td><td>109 (88.6%)</td><td>1 (reference)</td><td/></tr>
###xml 2062 2080 2062 2080 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;ValLeu and LeuLeu</td>
###xml 2080 2090 2080 2090 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">14 (16.3%)</td>
###xml 2090 2100 2090 2100 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">72 (83.7%)</td>
###xml 2100 2113 2100 2113 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1.2 (0.5&#8211;2.6)</td>
###xml 2113 2115 2113 2115 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NA</td>
###xml 2062 2115 2062 2115 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;ValLeu and LeuLeu</td><td>14 (16.3%)</td><td>72 (83.7%)</td><td>1.2 (0.5&#8211;2.6)</td><td>NA</td></tr>
###xml 2115 2132 2115 2132 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">FXIII A Tyr204Phe</td>
###xml 2132 2159 2132 2159 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Secondary cerebral ischemia</td>
###xml 2159 2189 2159 2189 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">No secondary cerebral ischemia</td>
###xml 2189 2189 2189 2189 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2189 2189 2189 2189 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2115 2189 2115 2189 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>FXIII A Tyr204Phe</td><td>Secondary cerebral ischemia</td><td>No secondary cerebral ischemia</td><td/><td/></tr>
###xml 2189 2196 2189 2196 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;TyrTyr</td>
###xml 2196 2206 2196 2206 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">44 (23.4%)</td>
###xml 2206 2217 2206 2217 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">144 (76.6%)</td>
###xml 2217 2230 2217 2230 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1 (reference)</td>
###xml 2230 2243 2230 2243 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1 (reference)</td>
###xml 2189 2243 2189 2243 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;TyrTyr</td><td>44 (23.4%)</td><td>144 (76.6%)</td><td>1 (reference)</td><td>1 (reference)</td></tr>
###xml 2243 2261 2243 2261 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;TyrPhe and PhePhe</td>
###xml 2261 2270 2261 2270 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">4 (21.1%)</td>
###xml 2270 2280 2270 2280 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">15 (78.9%)</td>
###xml 2280 2293 2280 2293 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0.9 (0.3&#8211;2.4)</td>
###xml 2293 2306 2293 2306 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0.9 (0.3&#8211;2.4)</td>
###xml 2243 2306 2243 2306 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;TyrPhe and PhePhe</td><td>4 (21.1%)</td><td>15 (78.9%)</td><td>0.9 (0.3&#8211;2.4)</td><td>0.9 (0.3&#8211;2.4)</td></tr>
###xml 2306 2306 2306 2306 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2306 2316 2306 2316 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Rebleeding</td>
###xml 2316 2329 2316 2329 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">No rebleeding</td>
###xml 2329 2329 2329 2329 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2329 2329 2329 2329 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2306 2329 2306 2329 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td/><td>Rebleeding</td><td>No rebleeding</td><td/><td/></tr>
###xml 2329 2336 2329 2336 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;TyrTyr</td>
###xml 2336 2346 2336 2346 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">27 (14.3%)</td>
###xml 2346 2357 2346 2357 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">162 (85.7%)</td>
###xml 2357 2370 2357 2370 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1 (reference)</td>
###xml 2370 2370 2370 2370 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2329 2370 2329 2370 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;TyrTyr</td><td>27 (14.3%)</td><td>162 (85.7%)</td><td>1 (reference)</td><td/></tr>
###xml 2370 2388 2370 2388 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;TyrPhe and PhePhe</td>
###xml 2388 2396 2388 2396 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1 (5.3%)</td>
###xml 2396 2406 2396 2406 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">18 (94.7%)</td>
###xml 2406 2419 2406 2419 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0.3 (0.0&#8211;2.5)</td>
###xml 2419 2421 2419 2421 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NA</td>
###xml 2370 2421 2370 2421 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;TyrPhe and PhePhe</td><td>1 (5.3%)</td><td>18 (94.7%)</td><td>0.3 (0.0&#8211;2.5)</td><td>NA</td></tr>
###xml 2421 2438 2421 2438 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">FXIII A Pro564Leu</td>
###xml 2438 2465 2438 2465 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Secondary cerebral ischemia</td>
###xml 2465 2495 2465 2495 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">No secondary cerebral ischemia</td>
###xml 2495 2495 2495 2495 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2495 2495 2495 2495 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2421 2495 2421 2495 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>FXIII A Pro564Leu</td><td>Secondary cerebral ischemia</td><td>No secondary cerebral ischemia</td><td/><td/></tr>
###xml 2495 2502 2495 2502 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;ProPro</td>
###xml 2502 2512 2502 2512 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">31 (27.2%)</td>
###xml 2512 2522 2512 2522 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">83 (72.8%)</td>
###xml 2522 2535 2522 2535 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1 (reference)</td>
###xml 2535 2548 2535 2548 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1 (reference)</td>
###xml 2495 2548 2495 2548 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;ProPro</td><td>31 (27.2%)</td><td>83 (72.8%)</td><td>1 (reference)</td><td>1 (reference)</td></tr>
###xml 2548 2566 2548 2566 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;ProLeu and LeuLeu</td>
###xml 2566 2576 2566 2576 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">17 (21.3%)</td>
###xml 2576 2586 2576 2586 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">63 (78.8%)</td>
###xml 2586 2599 2586 2599 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0.8 (0.4&#8211;1.4)</td>
###xml 2599 2612 2599 2612 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0.8 (0.4&#8211;1.4)</td>
###xml 2548 2612 2548 2612 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;ProLeu and LeuLeu</td><td>17 (21.3%)</td><td>63 (78.8%)</td><td>0.8 (0.4&#8211;1.4)</td><td>0.8 (0.4&#8211;1.4)</td></tr>
###xml 2612 2612 2612 2612 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2612 2622 2612 2622 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Rebleeding</td>
###xml 2622 2635 2622 2635 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">No rebleeding</td>
###xml 2635 2635 2635 2635 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2635 2635 2635 2635 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2612 2635 2612 2635 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td/><td>Rebleeding</td><td>No rebleeding</td><td/><td/></tr>
###xml 2635 2642 2635 2642 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;ProPro</td>
###xml 2642 2652 2642 2652 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">12 (10.5%)</td>
###xml 2652 2663 2652 2663 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">102 (89.5%)</td>
###xml 2663 2676 2663 2676 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1 (reference)</td>
###xml 2676 2676 2676 2676 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2635 2676 2635 2676 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;ProPro</td><td>12 (10.5%)</td><td>102 (89.5%)</td><td>1 (reference)</td><td/></tr>
###xml 2676 2694 2676 2694 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;ProLeu and LeuLeu</td>
###xml 2694 2704 2694 2704 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">14 (17.5%)</td>
###xml 2704 2714 2704 2714 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">66 (82.5%)</td>
###xml 2714 2727 2714 2727 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1.8 (0.8&#8211;4.2)</td>
###xml 2727 2729 2727 2729 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NA</td>
###xml 2676 2729 2676 2729 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;ProLeu and LeuLeu</td><td>14 (17.5%)</td><td>66 (82.5%)</td><td>1.8 (0.8&#8211;4.2)</td><td>NA</td></tr>
###xml 2729 2745 2729 2745 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">FXIII B His95Arg</td>
###xml 2745 2772 2745 2772 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Secondary cerebral ischemia</td>
###xml 2772 2802 2772 2802 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">No secondary cerebral ischemia</td>
###xml 2802 2802 2802 2802 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2802 2802 2802 2802 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2729 2802 2729 2802 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>FXIII B His95Arg</td><td>Secondary cerebral ischemia</td><td>No secondary cerebral ischemia</td><td/><td/></tr>
###xml 2802 2809 2802 2809 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;HisHis</td>
###xml 2809 2819 2809 2819 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">33 (21.9%)</td>
###xml 2819 2830 2819 2830 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">118 (78.1%)</td>
###xml 2830 2843 2830 2843 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1 (reference)</td>
###xml 2843 2843 2843 2843 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2802 2843 2802 2843 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;HisHis</td><td>33 (21.9%)</td><td>118 (78.1%)</td><td>1 (reference)</td><td/></tr>
###xml 2843 2861 2843 2861 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;HisArg and ArgArg</td>
###xml 2861 2871 2861 2871 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">14 (31.1%)</td>
###xml 2871 2881 2871 2881 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">31 (68.9%)</td>
###xml 2881 2894 2881 2894 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1.5 (0.8&#8211;2.8)</td>
###xml 2894 2907 2894 2907 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1.6 (0.8&#8211;2.9)</td>
###xml 2843 2907 2843 2907 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;HisArg and ArgArg</td><td>14 (31.1%)</td><td>31 (68.9%)</td><td>1.5 (0.8&#8211;2.8)</td><td>1.6 (0.8&#8211;2.9)</td></tr>
###xml 2907 2907 2907 2907 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2907 2917 2907 2917 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Rebleeding</td>
###xml 2917 2930 2917 2930 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">No rebleeding</td>
###xml 2930 2930 2930 2930 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2930 2930 2930 2930 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2907 2930 2907 2930 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td/><td>Rebleeding</td><td>No rebleeding</td><td/><td/></tr>
###xml 2930 2937 2930 2937 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;HisHis</td>
###xml 2937 2947 2937 2947 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">18 (11.8%)</td>
###xml 2947 2958 2947 2958 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">134 (88.2%)</td>
###xml 2958 2971 2958 2971 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1 (reference)</td>
###xml 2971 2971 2971 2971 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2930 2971 2930 2971 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;HisHis</td><td>18 (11.8%)</td><td>134 (88.2%)</td><td>1 (reference)</td><td/></tr>
###xml 2971 2989 2971 2989 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">&#160;HisArg and ArgArg</td>
###xml 2989 2998 2989 2998 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">8 (17.8%)</td>
###xml 2998 3008 2998 3008 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">37 (82.2%)</td>
###xml 3008 3021 3008 3021 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">1.1 (0.4&#8211;2.9)</td>
###xml 3021 3023 3021 3023 <td xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">NA</td>
###xml 2971 3023 2971 3023 <tr xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><td>&#160;HisArg and ArgArg</td><td>8 (17.8%)</td><td>37 (82.2%)</td><td>1.1 (0.4&#8211;2.9)</td><td>NA</td></tr>
###xml 979 3023 979 3023 <tbody xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>FV Leiden</td><td>Secondary cerebral ischemia</td><td>No secondary cerebral ischemia</td><td/><td/></tr><tr><td>&#160;GG</td><td>45 (23.0%)</td><td>151 (77.0%)</td><td>1 (reference)</td><td>1 (reference)</td></tr><tr><td>&#160;GA and AA</td><td>4 (36.4%)</td><td>7 (63.6%)</td><td>1.8 (0.6&#8211;4.9)</td><td>1.8 (0.6&#8211;5.0)</td></tr><tr><td/><td>Rebleeding</td><td>No rebleeding</td><td/><td/></tr><tr><td>&#160;GG</td><td>26 (13.2%)</td><td>171 (86.8%)</td><td>1 (reference)</td><td/></tr><tr><td>&#160;GA and AA</td><td>1 (9.1%)</td><td>10 (90.9%)</td><td>0.6 (0.1&#8211;4.5)</td><td>NA</td></tr><tr><td>Prothrombin G20210A</td><td>Secondary cerebral ischemia</td><td>No secondary cerebral ischemia</td><td/><td/></tr><tr><td>&#160;GG</td><td>48 (24.0%)</td><td>152 (76.0%)</td><td>1 (reference)</td><td>1 (reference)</td></tr><tr><td>&#160;GA and AA</td><td>1 (14.3%)</td><td>6 (85.7%)</td><td>0.5 (0.1&#8211;3.9)</td><td>0.5 (0.1&#8211;3.9)</td></tr><tr><td/><td>Rebleeding</td><td>No rebleeding</td><td/><td/></tr><tr><td>&#160;GG</td><td>27 (13.4%)</td><td>174 (86.6%)</td><td>1 (reference)</td><td/></tr><tr><td>&#160;GA and AA</td><td>0 (0%)</td><td>7 (100%)</td><td>0.7 (0.1&#8211;5.4)</td><td>NA</td></tr><tr><td>MTHFR C677T</td><td>Secondary cerebral ischemia</td><td>No secondary cerebral ischemia</td><td/><td/></tr><tr><td>&#160;CC and CT</td><td>47 (25.4%)</td><td>138 (74.6%)</td><td>1 (reference)</td><td>1 (reference)</td></tr><tr><td>&#160;TT</td><td>2 (9.1%)</td><td>20 (90.9%)</td><td>0.4 (0.1&#8211;1.5)</td><td>0.4 (0.1&#8211;1.5)</td></tr><tr><td/><td>Rebleeding</td><td>No rebleeding</td><td/><td/></tr><tr><td>&#160;CC and CT</td><td>22 (11.9%)</td><td>163 (88.1%)</td><td>1 (reference)</td><td/></tr><tr><td>&#160;TT</td><td>4 (18.2%)</td><td>18 (81.8%)</td><td>0.6 (0.2&#8211;1.7)</td><td>NA</td></tr><tr><td>FXIII A Val34Leu</td><td>Secondary cerebral ischemia</td><td>No secondary cerebral ischemia</td><td/><td/></tr><tr><td>&#160;ValVal</td><td>30 (24.62%)</td><td>92 (75.4%)</td><td>1 (reference)</td><td>1 (reference)</td></tr><tr><td>&#160;ValLeu and LeuLeu</td><td>18 (20.9%)</td><td>68 (79.1%)</td><td>0.9 (0.5&#8211;1.6)</td><td>0.9 (0.5&#8211;1.6)</td></tr><tr><td/><td>Rebleeding</td><td>No rebleeding</td><td/><td/></tr><tr><td>&#160;ValVal</td><td>14 (11.4%)</td><td>109 (88.6%)</td><td>1 (reference)</td><td/></tr><tr><td>&#160;ValLeu and LeuLeu</td><td>14 (16.3%)</td><td>72 (83.7%)</td><td>1.2 (0.5&#8211;2.6)</td><td>NA</td></tr><tr><td>FXIII A Tyr204Phe</td><td>Secondary cerebral ischemia</td><td>No secondary cerebral ischemia</td><td/><td/></tr><tr><td>&#160;TyrTyr</td><td>44 (23.4%)</td><td>144 (76.6%)</td><td>1 (reference)</td><td>1 (reference)</td></tr><tr><td>&#160;TyrPhe and PhePhe</td><td>4 (21.1%)</td><td>15 (78.9%)</td><td>0.9 (0.3&#8211;2.4)</td><td>0.9 (0.3&#8211;2.4)</td></tr><tr><td/><td>Rebleeding</td><td>No rebleeding</td><td/><td/></tr><tr><td>&#160;TyrTyr</td><td>27 (14.3%)</td><td>162 (85.7%)</td><td>1 (reference)</td><td/></tr><tr><td>&#160;TyrPhe and PhePhe</td><td>1 (5.3%)</td><td>18 (94.7%)</td><td>0.3 (0.0&#8211;2.5)</td><td>NA</td></tr><tr><td>FXIII A Pro564Leu</td><td>Secondary cerebral ischemia</td><td>No secondary cerebral ischemia</td><td/><td/></tr><tr><td>&#160;ProPro</td><td>31 (27.2%)</td><td>83 (72.8%)</td><td>1 (reference)</td><td>1 (reference)</td></tr><tr><td>&#160;ProLeu and LeuLeu</td><td>17 (21.3%)</td><td>63 (78.8%)</td><td>0.8 (0.4&#8211;1.4)</td><td>0.8 (0.4&#8211;1.4)</td></tr><tr><td/><td>Rebleeding</td><td>No rebleeding</td><td/><td/></tr><tr><td>&#160;ProPro</td><td>12 (10.5%)</td><td>102 (89.5%)</td><td>1 (reference)</td><td/></tr><tr><td>&#160;ProLeu and LeuLeu</td><td>14 (17.5%)</td><td>66 (82.5%)</td><td>1.8 (0.8&#8211;4.2)</td><td>NA</td></tr><tr><td>FXIII B His95Arg</td><td>Secondary cerebral ischemia</td><td>No secondary cerebral ischemia</td><td/><td/></tr><tr><td>&#160;HisHis</td><td>33 (21.9%)</td><td>118 (78.1%)</td><td>1 (reference)</td><td/></tr><tr><td>&#160;HisArg and ArgArg</td><td>14 (31.1%)</td><td>31 (68.9%)</td><td>1.5 (0.8&#8211;2.8)</td><td>1.6 (0.8&#8211;2.9)</td></tr><tr><td/><td>Rebleeding</td><td>No rebleeding</td><td/><td/></tr><tr><td>&#160;HisHis</td><td>18 (11.8%)</td><td>134 (88.2%)</td><td>1 (reference)</td><td/></tr><tr><td>&#160;HisArg and ArgArg</td><td>8 (17.8%)</td><td>37 (82.2%)</td><td>1.1 (0.4&#8211;2.9)</td><td>NA</td></tr></tbody>
###xml 886 3023 886 3023 <table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>Genotype</th><th>Complication</th><th>No complication</th><th>Crude hazard ratio (95% CI)</th><th>Adjusted hazard ratio (95% CI)*</th></tr></thead><tbody><tr><td>FV Leiden</td><td>Secondary cerebral ischemia</td><td>No secondary cerebral ischemia</td><td/><td/></tr><tr><td>&#160;GG</td><td>45 (23.0%)</td><td>151 (77.0%)</td><td>1 (reference)</td><td>1 (reference)</td></tr><tr><td>&#160;GA and AA</td><td>4 (36.4%)</td><td>7 (63.6%)</td><td>1.8 (0.6&#8211;4.9)</td><td>1.8 (0.6&#8211;5.0)</td></tr><tr><td/><td>Rebleeding</td><td>No rebleeding</td><td/><td/></tr><tr><td>&#160;GG</td><td>26 (13.2%)</td><td>171 (86.8%)</td><td>1 (reference)</td><td/></tr><tr><td>&#160;GA and AA</td><td>1 (9.1%)</td><td>10 (90.9%)</td><td>0.6 (0.1&#8211;4.5)</td><td>NA</td></tr><tr><td>Prothrombin G20210A</td><td>Secondary cerebral ischemia</td><td>No secondary cerebral ischemia</td><td/><td/></tr><tr><td>&#160;GG</td><td>48 (24.0%)</td><td>152 (76.0%)</td><td>1 (reference)</td><td>1 (reference)</td></tr><tr><td>&#160;GA and AA</td><td>1 (14.3%)</td><td>6 (85.7%)</td><td>0.5 (0.1&#8211;3.9)</td><td>0.5 (0.1&#8211;3.9)</td></tr><tr><td/><td>Rebleeding</td><td>No rebleeding</td><td/><td/></tr><tr><td>&#160;GG</td><td>27 (13.4%)</td><td>174 (86.6%)</td><td>1 (reference)</td><td/></tr><tr><td>&#160;GA and AA</td><td>0 (0%)</td><td>7 (100%)</td><td>0.7 (0.1&#8211;5.4)</td><td>NA</td></tr><tr><td>MTHFR C677T</td><td>Secondary cerebral ischemia</td><td>No secondary cerebral ischemia</td><td/><td/></tr><tr><td>&#160;CC and CT</td><td>47 (25.4%)</td><td>138 (74.6%)</td><td>1 (reference)</td><td>1 (reference)</td></tr><tr><td>&#160;TT</td><td>2 (9.1%)</td><td>20 (90.9%)</td><td>0.4 (0.1&#8211;1.5)</td><td>0.4 (0.1&#8211;1.5)</td></tr><tr><td/><td>Rebleeding</td><td>No rebleeding</td><td/><td/></tr><tr><td>&#160;CC and CT</td><td>22 (11.9%)</td><td>163 (88.1%)</td><td>1 (reference)</td><td/></tr><tr><td>&#160;TT</td><td>4 (18.2%)</td><td>18 (81.8%)</td><td>0.6 (0.2&#8211;1.7)</td><td>NA</td></tr><tr><td>FXIII A Val34Leu</td><td>Secondary cerebral ischemia</td><td>No secondary cerebral ischemia</td><td/><td/></tr><tr><td>&#160;ValVal</td><td>30 (24.62%)</td><td>92 (75.4%)</td><td>1 (reference)</td><td>1 (reference)</td></tr><tr><td>&#160;ValLeu and LeuLeu</td><td>18 (20.9%)</td><td>68 (79.1%)</td><td>0.9 (0.5&#8211;1.6)</td><td>0.9 (0.5&#8211;1.6)</td></tr><tr><td/><td>Rebleeding</td><td>No rebleeding</td><td/><td/></tr><tr><td>&#160;ValVal</td><td>14 (11.4%)</td><td>109 (88.6%)</td><td>1 (reference)</td><td/></tr><tr><td>&#160;ValLeu and LeuLeu</td><td>14 (16.3%)</td><td>72 (83.7%)</td><td>1.2 (0.5&#8211;2.6)</td><td>NA</td></tr><tr><td>FXIII A Tyr204Phe</td><td>Secondary cerebral ischemia</td><td>No secondary cerebral ischemia</td><td/><td/></tr><tr><td>&#160;TyrTyr</td><td>44 (23.4%)</td><td>144 (76.6%)</td><td>1 (reference)</td><td>1 (reference)</td></tr><tr><td>&#160;TyrPhe and PhePhe</td><td>4 (21.1%)</td><td>15 (78.9%)</td><td>0.9 (0.3&#8211;2.4)</td><td>0.9 (0.3&#8211;2.4)</td></tr><tr><td/><td>Rebleeding</td><td>No rebleeding</td><td/><td/></tr><tr><td>&#160;TyrTyr</td><td>27 (14.3%)</td><td>162 (85.7%)</td><td>1 (reference)</td><td/></tr><tr><td>&#160;TyrPhe and PhePhe</td><td>1 (5.3%)</td><td>18 (94.7%)</td><td>0.3 (0.0&#8211;2.5)</td><td>NA</td></tr><tr><td>FXIII A Pro564Leu</td><td>Secondary cerebral ischemia</td><td>No secondary cerebral ischemia</td><td/><td/></tr><tr><td>&#160;ProPro</td><td>31 (27.2%)</td><td>83 (72.8%)</td><td>1 (reference)</td><td>1 (reference)</td></tr><tr><td>&#160;ProLeu and LeuLeu</td><td>17 (21.3%)</td><td>63 (78.8%)</td><td>0.8 (0.4&#8211;1.4)</td><td>0.8 (0.4&#8211;1.4)</td></tr><tr><td/><td>Rebleeding</td><td>No rebleeding</td><td/><td/></tr><tr><td>&#160;ProPro</td><td>12 (10.5%)</td><td>102 (89.5%)</td><td>1 (reference)</td><td/></tr><tr><td>&#160;ProLeu and LeuLeu</td><td>14 (17.5%)</td><td>66 (82.5%)</td><td>1.8 (0.8&#8211;4.2)</td><td>NA</td></tr><tr><td>FXIII B His95Arg</td><td>Secondary cerebral ischemia</td><td>No secondary cerebral ischemia</td><td/><td/></tr><tr><td>&#160;HisHis</td><td>33 (21.9%)</td><td>118 (78.1%)</td><td>1 (reference)</td><td/></tr><tr><td>&#160;HisArg and ArgArg</td><td>14 (31.1%)</td><td>31 (68.9%)</td><td>1.5 (0.8&#8211;2.8)</td><td>1.6 (0.8&#8211;2.9)</td></tr><tr><td/><td>Rebleeding</td><td>No rebleeding</td><td/><td/></tr><tr><td>&#160;HisHis</td><td>18 (11.8%)</td><td>134 (88.2%)</td><td>1 (reference)</td><td/></tr><tr><td>&#160;HisArg and ArgArg</td><td>8 (17.8%)</td><td>37 (82.2%)</td><td>1.1 (0.4&#8211;2.9)</td><td>NA</td></tr></tbody></table>
###xml 3023 3108 3023 3108 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="35">*Adjusted for clinical condition on admission and amount of blood on initial CT scan.</p>
###xml 3108 3153 3108 3153 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" textid="36">CI = confidence interval; NA = not applicable</p>
###xml 3023 3153 3023 3153 <table-wrap-foot xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="35">*Adjusted for clinical condition on admission and amount of blood on initial CT scan.</p><p textid="36">CI = confidence interval; NA = not applicable</p></table-wrap-foot>
###xml 748 3153 748 3153 <table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab3"><label>Table&#160;3</label><caption><p textid="34">Hazard ratios for risk of secondary cerebral ischemia and rebleeding after aneurysmal subarachnoid hemorrhage according to genotype</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Genotype</th><th>Complication</th><th>No complication</th><th>Crude hazard ratio (95% CI)</th><th>Adjusted hazard ratio (95% CI)*</th></tr></thead><tbody><tr><td>FV Leiden</td><td>Secondary cerebral ischemia</td><td>No secondary cerebral ischemia</td><td/><td/></tr><tr><td>&#160;GG</td><td>45 (23.0%)</td><td>151 (77.0%)</td><td>1 (reference)</td><td>1 (reference)</td></tr><tr><td>&#160;GA and AA</td><td>4 (36.4%)</td><td>7 (63.6%)</td><td>1.8 (0.6&#8211;4.9)</td><td>1.8 (0.6&#8211;5.0)</td></tr><tr><td/><td>Rebleeding</td><td>No rebleeding</td><td/><td/></tr><tr><td>&#160;GG</td><td>26 (13.2%)</td><td>171 (86.8%)</td><td>1 (reference)</td><td/></tr><tr><td>&#160;GA and AA</td><td>1 (9.1%)</td><td>10 (90.9%)</td><td>0.6 (0.1&#8211;4.5)</td><td>NA</td></tr><tr><td>Prothrombin G20210A</td><td>Secondary cerebral ischemia</td><td>No secondary cerebral ischemia</td><td/><td/></tr><tr><td>&#160;GG</td><td>48 (24.0%)</td><td>152 (76.0%)</td><td>1 (reference)</td><td>1 (reference)</td></tr><tr><td>&#160;GA and AA</td><td>1 (14.3%)</td><td>6 (85.7%)</td><td>0.5 (0.1&#8211;3.9)</td><td>0.5 (0.1&#8211;3.9)</td></tr><tr><td/><td>Rebleeding</td><td>No rebleeding</td><td/><td/></tr><tr><td>&#160;GG</td><td>27 (13.4%)</td><td>174 (86.6%)</td><td>1 (reference)</td><td/></tr><tr><td>&#160;GA and AA</td><td>0 (0%)</td><td>7 (100%)</td><td>0.7 (0.1&#8211;5.4)</td><td>NA</td></tr><tr><td>MTHFR C677T</td><td>Secondary cerebral ischemia</td><td>No secondary cerebral ischemia</td><td/><td/></tr><tr><td>&#160;CC and CT</td><td>47 (25.4%)</td><td>138 (74.6%)</td><td>1 (reference)</td><td>1 (reference)</td></tr><tr><td>&#160;TT</td><td>2 (9.1%)</td><td>20 (90.9%)</td><td>0.4 (0.1&#8211;1.5)</td><td>0.4 (0.1&#8211;1.5)</td></tr><tr><td/><td>Rebleeding</td><td>No rebleeding</td><td/><td/></tr><tr><td>&#160;CC and CT</td><td>22 (11.9%)</td><td>163 (88.1%)</td><td>1 (reference)</td><td/></tr><tr><td>&#160;TT</td><td>4 (18.2%)</td><td>18 (81.8%)</td><td>0.6 (0.2&#8211;1.7)</td><td>NA</td></tr><tr><td>FXIII A Val34Leu</td><td>Secondary cerebral ischemia</td><td>No secondary cerebral ischemia</td><td/><td/></tr><tr><td>&#160;ValVal</td><td>30 (24.62%)</td><td>92 (75.4%)</td><td>1 (reference)</td><td>1 (reference)</td></tr><tr><td>&#160;ValLeu and LeuLeu</td><td>18 (20.9%)</td><td>68 (79.1%)</td><td>0.9 (0.5&#8211;1.6)</td><td>0.9 (0.5&#8211;1.6)</td></tr><tr><td/><td>Rebleeding</td><td>No rebleeding</td><td/><td/></tr><tr><td>&#160;ValVal</td><td>14 (11.4%)</td><td>109 (88.6%)</td><td>1 (reference)</td><td/></tr><tr><td>&#160;ValLeu and LeuLeu</td><td>14 (16.3%)</td><td>72 (83.7%)</td><td>1.2 (0.5&#8211;2.6)</td><td>NA</td></tr><tr><td>FXIII A Tyr204Phe</td><td>Secondary cerebral ischemia</td><td>No secondary cerebral ischemia</td><td/><td/></tr><tr><td>&#160;TyrTyr</td><td>44 (23.4%)</td><td>144 (76.6%)</td><td>1 (reference)</td><td>1 (reference)</td></tr><tr><td>&#160;TyrPhe and PhePhe</td><td>4 (21.1%)</td><td>15 (78.9%)</td><td>0.9 (0.3&#8211;2.4)</td><td>0.9 (0.3&#8211;2.4)</td></tr><tr><td/><td>Rebleeding</td><td>No rebleeding</td><td/><td/></tr><tr><td>&#160;TyrTyr</td><td>27 (14.3%)</td><td>162 (85.7%)</td><td>1 (reference)</td><td/></tr><tr><td>&#160;TyrPhe and PhePhe</td><td>1 (5.3%)</td><td>18 (94.7%)</td><td>0.3 (0.0&#8211;2.5)</td><td>NA</td></tr><tr><td>FXIII A Pro564Leu</td><td>Secondary cerebral ischemia</td><td>No secondary cerebral ischemia</td><td/><td/></tr><tr><td>&#160;ProPro</td><td>31 (27.2%)</td><td>83 (72.8%)</td><td>1 (reference)</td><td>1 (reference)</td></tr><tr><td>&#160;ProLeu and LeuLeu</td><td>17 (21.3%)</td><td>63 (78.8%)</td><td>0.8 (0.4&#8211;1.4)</td><td>0.8 (0.4&#8211;1.4)</td></tr><tr><td/><td>Rebleeding</td><td>No rebleeding</td><td/><td/></tr><tr><td>&#160;ProPro</td><td>12 (10.5%)</td><td>102 (89.5%)</td><td>1 (reference)</td><td/></tr><tr><td>&#160;ProLeu and LeuLeu</td><td>14 (17.5%)</td><td>66 (82.5%)</td><td>1.8 (0.8&#8211;4.2)</td><td>NA</td></tr><tr><td>FXIII B His95Arg</td><td>Secondary cerebral ischemia</td><td>No secondary cerebral ischemia</td><td/><td/></tr><tr><td>&#160;HisHis</td><td>33 (21.9%)</td><td>118 (78.1%)</td><td>1 (reference)</td><td/></tr><tr><td>&#160;HisArg and ArgArg</td><td>14 (31.1%)</td><td>31 (68.9%)</td><td>1.5 (0.8&#8211;2.8)</td><td>1.6 (0.8&#8211;2.9)</td></tr><tr><td/><td>Rebleeding</td><td>No rebleeding</td><td/><td/></tr><tr><td>&#160;HisHis</td><td>18 (11.8%)</td><td>134 (88.2%)</td><td>1 (reference)</td><td/></tr><tr><td>&#160;HisArg and ArgArg</td><td>8 (17.8%)</td><td>37 (82.2%)</td><td>1.1 (0.4&#8211;2.9)</td><td>NA</td></tr></tbody></table><table-wrap-foot><p textid="35">*Adjusted for clinical condition on admission and amount of blood on initial CT scan.</p><p textid="36">CI = confidence interval; NA = not applicable</p></table-wrap-foot></table-wrap>
Table 3 shows the HR for the risk of secondary cerebral ischemia and rebleeding according to genotype. A clear relation with the risk of secondary cerebral ischemia and of rebleeding could not be established for any of these genetic variants. However, for some polymorphisms, an association was observed, although with wide confidence intervals. Notably, for the factor V Leiden polymorphism that has been proven to be associated with an increased risk of thrombosis in previous studies [5], we found a moderately increased risk of secondary cerebral ischemia (crude HR 1.8, 95% CI 0.6-4.9 and adjusted HR 1.8, 95% CI 0.6-5.0) and an opposite lower risk of rebleeding (HR 0.6, 95% CI 0.1-4.5), although this did not reach statistical significance. Table 3Hazard ratios for risk of secondary cerebral ischemia and rebleeding after aneurysmal subarachnoid hemorrhage according to genotypeGenotypeComplicationNo complicationCrude hazard ratio (95% CI)Adjusted hazard ratio (95% CI)*FV LeidenSecondary cerebral ischemiaNo secondary cerebral ischemia GG45 (23.0%)151 (77.0%)1 (reference)1 (reference) GA and AA4 (36.4%)7 (63.6%)1.8 (0.6-4.9)1.8 (0.6-5.0)RebleedingNo rebleeding GG26 (13.2%)171 (86.8%)1 (reference) GA and AA1 (9.1%)10 (90.9%)0.6 (0.1-4.5)NAProthrombin G20210ASecondary cerebral ischemiaNo secondary cerebral ischemia GG48 (24.0%)152 (76.0%)1 (reference)1 (reference) GA and AA1 (14.3%)6 (85.7%)0.5 (0.1-3.9)0.5 (0.1-3.9)RebleedingNo rebleeding GG27 (13.4%)174 (86.6%)1 (reference) GA and AA0 (0%)7 (100%)0.7 (0.1-5.4)NAMTHFR C677TSecondary cerebral ischemiaNo secondary cerebral ischemia CC and CT47 (25.4%)138 (74.6%)1 (reference)1 (reference) TT2 (9.1%)20 (90.9%)0.4 (0.1-1.5)0.4 (0.1-1.5)RebleedingNo rebleeding CC and CT22 (11.9%)163 (88.1%)1 (reference) TT4 (18.2%)18 (81.8%)0.6 (0.2-1.7)NAFXIII A Val34LeuSecondary cerebral ischemiaNo secondary cerebral ischemia ValVal30 (24.62%)92 (75.4%)1 (reference)1 (reference) ValLeu and LeuLeu18 (20.9%)68 (79.1%)0.9 (0.5-1.6)0.9 (0.5-1.6)RebleedingNo rebleeding ValVal14 (11.4%)109 (88.6%)1 (reference) ValLeu and LeuLeu14 (16.3%)72 (83.7%)1.2 (0.5-2.6)NAFXIII A Tyr204PheSecondary cerebral ischemiaNo secondary cerebral ischemia TyrTyr44 (23.4%)144 (76.6%)1 (reference)1 (reference) TyrPhe and PhePhe4 (21.1%)15 (78.9%)0.9 (0.3-2.4)0.9 (0.3-2.4)RebleedingNo rebleeding TyrTyr27 (14.3%)162 (85.7%)1 (reference) TyrPhe and PhePhe1 (5.3%)18 (94.7%)0.3 (0.0-2.5)NAFXIII A Pro564LeuSecondary cerebral ischemiaNo secondary cerebral ischemia ProPro31 (27.2%)83 (72.8%)1 (reference)1 (reference) ProLeu and LeuLeu17 (21.3%)63 (78.8%)0.8 (0.4-1.4)0.8 (0.4-1.4)RebleedingNo rebleeding ProPro12 (10.5%)102 (89.5%)1 (reference) ProLeu and LeuLeu14 (17.5%)66 (82.5%)1.8 (0.8-4.2)NAFXIII B His95ArgSecondary cerebral ischemiaNo secondary cerebral ischemia HisHis33 (21.9%)118 (78.1%)1 (reference) HisArg and ArgArg14 (31.1%)31 (68.9%)1.5 (0.8-2.8)1.6 (0.8-2.9)RebleedingNo rebleeding HisHis18 (11.8%)134 (88.2%)1 (reference) HisArg and ArgArg8 (17.8%)37 (82.2%)1.1 (0.4-2.9)NA*Adjusted for clinical condition on admission and amount of blood on initial CT scan.CI = confidence interval; NA = not applicable
###end p 33
###begin p 34
Hazard ratios for risk of secondary cerebral ischemia and rebleeding after aneurysmal subarachnoid hemorrhage according to genotype
###end p 34
###begin p 35
*Adjusted for clinical condition on admission and amount of blood on initial CT scan.
###end p 35
###begin p 36
CI = confidence interval; NA = not applicable
###end p 36
###begin title 37
Discussion
###end title 37
###begin p 38
###xml 194 202 <span type="species:ncbi:9606">patients</span>
This study was performed to analyze whether genes influencing coagulation are associated with the occurrence of aneurysmal SAH and with the risk of secondary cerebral ischemia and rebleeding in patients with aneurysmal SAH. Polymorphisms in the factor V Leiden, prothrombin G20210A, MTHFR C677T, subunit A Val34Leu, Tyr204Phe and Pro564Leu factor XIII and subunit B His95Arg factor XIII were investigated.
###end p 38
###begin p 39
###xml 547 549 547 549 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 756 758 756 758 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 72 80 <span type="species:ncbi:9606">patients</span>
###xml 987 994 <span type="species:ncbi:9606">patient</span>
###xml 1111 1119 <span type="species:ncbi:9606">patients</span>
With regard to the risk of aneurysmal SAH, we found that aneurysmal SAH patients are more often carriers of the subunit B His95Arg factor XIII polymorphism compared to controls. This suggests that carriers of the subunit B His95Arg factor XIII polymorphism have an increased risk of aneurysmal SAH. As yet not much is known about the His95Arg polymorphism in the factor XIII subunit B. One study suggested the Arg95 variant to be associated with an increased risk of thrombosis in combination with an increased factor XIII subunit B dissociation [18]. Our finding that the His95Arg factor XIII subunit B polymorphism is associated with an increased risk of aneurysmal SAH is not consistent with the previous observation of an increased risk of thrombosis [18]. Further studies investigating the influence of this variant on the risk of thrombosis and bleeding are needed. Ideally, we would have analyzed data on the coagulation system and the overall thrombosis and bleeding risk in our patient group and related those data to the polymorphisms studied. Unfortunately, we do not have these data for our studied patients.
###end p 39
###begin p 40
###xml 131 139 <span type="species:ncbi:9606">patients</span>
###xml 394 402 <span type="species:ncbi:9606">patients</span>
On analyzing the association of genes influencing coagulation with the occurrence of secondary cerebral ischemia and rebleeding in patients with aneurysmal SAH, no unequivocal, large effects could be demonstrated. This may be explained by the fact that our study population was relatively small. However, larger studies are difficult to perform as these should include approximately over 1,000 patients to demonstrate the small effects (HR of 1.5 or smaller) of the coagulation factors.
###end p 40
###begin p 41
###xml 116 117 116 117 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 243 251 <span type="species:ncbi:9606">patients</span>
Our findings do suggest that, consistent with the increased risk of thrombosis of the factor V Leiden polymorphism [5], factor V Leiden is associated with an increased risk of secondary ischemia and an opposite decreased risk of rebleeding in patients with aneurysmal SAH. These results should be interpreted with caution as the 95% CIs were wide for all the HR calculated in this study.
###end p 41
###begin p 42
###xml 419 421 419 421 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 423 425 423 425 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 15 23 <span type="species:ncbi:9606">patients</span>
###xml 192 200 <span type="species:ncbi:9606">patients</span>
###xml 274 282 <span type="species:ncbi:9606">patients</span>
###xml 328 336 <span type="species:ncbi:9606">patients</span>
###xml 466 474 <span type="species:ncbi:9606">patients</span>
Aneurysmal SAH patients who died soon after admission could not be included in the present study because they could not be asked to participate. Our results therefore apply to a population of patients who survived the initial hours after the hemorrhage. Not including these patients may have biased our results as some of these patients may have died because of early rebleeding within hours of the initial hemorrhage [10, 13], leading to an under representation of patients with rebleeding in our study.
###end p 42
###begin p 43
The results of this study suggest that genetic factors are involved in coagulation in the occurrence of aneurysmal SAH as we found evidence that carriers of the subunit B His95Arg factor XIII polymorphism are at increased risk. Larger studies should confirm our results. For the other studied polymorphisms involved in coagulation, no association with the occurrence of aneurysmal SAH or with the occurrence of secondary cerebral ischemia or rebleeding after aneurysmal SAH could be demonstrated.
###end p 43
###begin p 44
Y.M. Ruigrok was supported by The Netherlands Organization for Scientific Research (NWO), project no. 940-37-023.
###end p 44
###begin p 45
###xml 0 11 0 11 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Open Access</bold>
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 45
###begin title 46
References
###end title 46
###begin article-title 47
Predicting cerebral ischemia after aneurysmal subarachnoid hemorrhage: influence of clinical condition, CT results and antifibrinolytic therapy: a report from the Cooperative Aneurysm Study
###end article-title 47
###begin article-title 48
Genotype/phenotype correlations for coagulation factor XIII: specific normal polymorphisms are associated with high or low factor XIII specific activity
###end article-title 48
###begin article-title 49
The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure
###end article-title 49
###begin article-title 50
Magnesium sulfate in aneurysmal subarachnoid hemorrhage: a randomized controlled trial
###end article-title 50
###begin article-title 51
Mutation in blood coagulation factor V associated with resistance to activated protein C
###end article-title 51
###begin article-title 52
###xml 59 67 <span type="species:ncbi:9606">patients</span>
Rebleeding, secondary ischemia, and timing of operation in patients with subarachnoid hemorrhage
###end article-title 52
###begin article-title 53
Factor V Leiden protects against blood loss and transfusion after cardiac surgery
###end article-title 53
###begin article-title 54
Report of World Federation on Neurological Surgeons committee on a universal subarachnoid hemorrhage grading scale
###end article-title 54
###begin article-title 55
A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase
###end article-title 55
###begin article-title 56
Ultra-early rebleeding in spontaneous subarachnoid hemorrhage
###end article-title 56
###begin article-title 57
Grading the amount of blood on computed tomograms after subarachnoid hemorrhage
###end article-title 57
###begin article-title 58
Prediction of delayed cerebral ischemia, rebleeding, and outcome after aneurysmal subarachnoid hemorrhage
###end article-title 58
###begin article-title 59
Rerupture of intracranial aneurysms: a clinicoanatomic study
###end article-title 59
###begin article-title 60
Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study
###end article-title 60
###begin article-title 61
Case-fatality rates and functional outcome after subarachnoid hemorrhage: a systematic review
###end article-title 61
###begin article-title 62
The Val34Leu polymorphism in the A subunit of coagulation factor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity
###end article-title 62
###begin article-title 63
Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies
###end article-title 63
###begin article-title 64
A novel polymorphism in the factor XIII B-subunit (His95Arg): relationship to subunit dissociation and venous thrombosis
###end article-title 64
###begin article-title 65
Activated protein C resistance (FV:Q506) and pregnancy
###end article-title 65
###begin article-title 66
Incidence of subarachnoid hemorrhage. Role of region, year, and rate of computed tomography: a meta-analysis
###end article-title 66
###begin article-title 67
A study of blood coagulation and fibrinolytic system in spontaneous subarachnoid hemorrhage. Correlation with hunt-hess grade and outcome
###end article-title 67
###begin article-title 68
A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
###end article-title 68
###begin article-title 69
A statistical analysis of factors related to symptomatic cerebral vasospasm
###end article-title 69
###begin article-title 70
###xml 106 111 <span type="species:ncbi:9606">women</span>
Polymorphisms of coagulation factor XIII subunit A and risk of nonfatal hemorrhagic stroke in young white women
###end article-title 70
###begin article-title 71
Calcium antagonists for aneurysmal subarachnoid haemorrhage
###end article-title 71
###begin article-title 72
Subarachnoid hemorrhage without detectable aneurysm. A review of the causes
###end article-title 72
###begin article-title 73
###xml 21 29 <span type="species:ncbi:9606">patients</span>
Timing of surgery in patients with aneurysmal subarachnoid haemorrhage: rebleeding is still the major cause of poor outcome in neurosurgical units that aim at early surgery
###end article-title 73
###begin article-title 74
Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage
###end article-title 74
###begin article-title 75
Prothrombotic conditions, oral contraceptives and the risk of ischemic stroke
###end article-title 75
###begin article-title 76
Plasminogen activator inhibitor-1 4G allele in the 4G/5G promoter polymorphism increases the occurrence of cerebral ischemia after aneurysmal subarachnoid hemorrhage
###end article-title 76

